Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azvudine + tenofovir alafenamide fumarate
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Azvudine + tenofovir alafenamide fumarate** is a combination of two antiviral small molecules, both nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). **Azvudine** (FNC) inhibits HIV-1 reverse transcriptase and RNA-dependent RNA polymerase, originally developed for hepatitis C, now approved in China for HIV-1 and COVID-19. **Tenofovir alafenamide fumarate** (TAF, GS-7340) is a prodrug of tenofovir, providing enhanced delivery and reduced toxicity, approved globally as part of fixed-dose regimens for HIV-1 and hepatitis B[1][4]. Both act by chain termination during viral DNA synthesis[3][4]. The combination is being investigated for drug-drug interactions, with azvudine offering potential for broad antiviral coverage and improved tolerability in HIV co-formulations[3][4]. TAF is currently manufactured by Gilead for branded combinations, but no fixed-dose brand nor global approval currently exists for this dual combination.
- Brand names
- none known for this exact combination
- Other names
- azvudine + TAFazvudine + tenofovir alafenamide
02
Targets
HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptaseRdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on azvudine + tenofovir alafenamide fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azvudine + tenofovir alafenamide fumarate.